Pulchinenoside B

CAS No. 135247-95-9

Pulchinenoside B( ——— )

Catalog No. M38897 CAS No. 135247-95-9

Pulchinenoside B is a triterpenoid saponin isolated from Pulsatilla chinensis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Pulchinenoside B
  • Note
    Research use only, not for human use.
  • Brief Description
    Pulchinenoside B is a triterpenoid saponin isolated from Pulsatilla chinensis.
  • Description
    Pulchinenoside B is a triterpenoid saponin isolated from Pulsatilla chinensis.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    135247-95-9
  • Formula Weight
    1221.39
  • Molecular Formula
    C59H96O26
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wan JY, et al. Biotransformation and metabolic profile of anemoside B4 with rat small and large intestine microflora by ultra-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry. Biomed Chromatogr. 2017;31(5):10.1002/bmc.3873.?
molnova catalog
related products
  • Theasaponin E2

    Theasaponin E2 has antitumor activity.

  • Chrysophanol 1-O-bet...

    Chrysophanol 1-O-beta-tetraglucoside is a natural product.

  • ZINC77292789

    Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a reagent for the preparation of a synthetic MUC1 Glycopeptide Bearing βGalNAc-?Thr as a Tn antigen isomer which induces the antibody production against tumor cells. Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a starting material to make trimeric MUC1 immunodominant motif antigen-?based anti-?cancer vaccine candidates.